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Background: Neuromyelitis optica (NMO) is an inﬂammatory disease caused by the aquaporin (AQP)-4-anti-
body. Pathological studies on NMO have revealed extensive astrocytic damage, as evidenced by the loss of
AQP4 and glial ﬁbrillary acidic protein (GFAP), speciﬁcally in perivascular regions with immunoglobulin and
complement depositions, although other pathological patterns, such as a loss of AQP4 without astrocyte de-
struction and clasmatodendrosis, have also been observed. Previous studies have shown that complement-
dependent antibody-mediated astrocyte lysis is likely a major pathomechanism in NMO. However, there are
also data to suggest antibody-mediated astrocyte dysfunction in the absence of complement. Thus, the im-
portance of complement inhibitory proteins in complement-dependent AQP4-antibody-mediated astrocyte
lysis in NMO is unclear. In most of the previous studies, the complement and target cells (astrocytes or AQP4-
transfected cells) were derived from different species; however, the complement inhibitory proteins that are
expressed on the cell surface cannot protect themselves against complement-dependent cytolysis unless the
complements and complement inhibitory proteins are from the same species. To resolve these issues, we
studied human astrocytes in primary culture treated with AQP4-antibody in the presence or absence of human
complement and examined the effect of complement inhibitory proteins using small interfering RNA (siRNA).
Methods: Puriﬁed IgG (10 mg/mL) was obtained from 5 patients with AQP4-antibody-positive NMO, 3 patients
with multiple sclerosis (MS), and 3 healthy controls. Conﬂuent human astrocytes transfected with Venus-M1-
AQP4-cDNA were incubated with IgG (5% volume). After washing, we cultured the cells with human com-
plements with or without heat inactivation. We observed time-lapse morphological and immunohistochemical
changes using a ﬂuorescence microscope. We also evaluated cytotoxicity using a propidium iodide (PI) kit and
the lactate dehydrogenase (LDH) assay.
Result: AQP4-antibody alone caused clustering and degradation followed by endocytosis of membraneous
AQP4, thereby resulting in decreased cellular adherence and the shrinkage of astrocytic processes. However,
these changes were partially reversed by the removal of IgG in culture. In contrast, following the application of
AQP4-antibody and non-heated human complements, the cell bodies and nuclei started to swell. At 3 h, most
of the astrocytes had lost mobility and adherence and were eventually destroyed or had swollen andwere then
destroyed. In addition, the remaining adherent cells were mostly PI-positive, indicating necrosis. Astrocyte lysis
caused by rabbit complement occurred much faster than did cell lysis with human complement. However, the
cell lysis was signiﬁcantly enhanced by the transfection of astrocytes with siRNA against human CD55 and
CD59, which are major complement inhibitory proteins on the astrocyte membrane. AQP4-antibody-negative
IgG in MS or control did not induce such changes.
Conclusion: Taken together, these ﬁndings suggest that both complement-dependent and complement-in-
dependent AQP4-antibody-mediated astrocytopathies may operate in NMO, potentially contributing to diverse
pathological patterns. Our results also suggest that the effect of complement inhibitory proteins should be
considered when evaluating AQP4-antibody-mediated cytotoxicity in AQP4-expressing cells.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Neuromyelitis optica (NMO) is an inﬂammatory disease that is
characterized by severe optic neuritis and longitudinally extended
transverse myelitis. Aquaporin-4 (AQP4)-antibody is a diagnostic
biomarker of NMO [1]. AQP4 is a transmembrane water channel
that is richly expressed on the endfeet of astrocytes in the central
nervous system [2]. AQP4 has the two main isoforms: full-length
M1 and a shorter form, M23. Both isoforms are present in astro-
cytes, and endogenous AQP4 is a tetramer that consists of various
combinations of M1 and M23 subunits [3]. The expression ratios of
these AQP4 isoforms are different, but both isoforms are expressed
in the cerebrum, brainstem, spinal cord, and optic nerve [4]. Pa-
thological studies have revealed an extensive loss of AQP4 and
glial ﬁbrillary acidic protein (GFAP), an astrocytic cytoplasmic
protein, in perivascular regions with complement in NMO [5].
Other pathological patterns, including the loss of AQP4 without
astrocyte destruction and clasmatodendrosis, have also been ob-
served. There is a marked increase in GFAP in the cerebrospinal
ﬂuids during relapse of NMO [6]. A loss of AQP4 and GFAP has also
been observed in experimental autoimmune encephalomyelitis
with AQP4-antibody administration [7,8]. Taken together, these
ﬁndings suggest astrocyte lysis by complement-dependent AQP4-
antibody-mediated cytotoxicity to astrocytes. In addition, pure
AQP4 loss without astrocyte damage has been reported in neu-
ropathological studies of NMO [9–11]. Astrocyte lysis may also be
mediated by either complement-dependent cytotoxicity (CDC)
[12–17] or antibody-dependent cell-mediated cytotoxicity [18–20],
and AQP4 loss without astrocyte lysis might be caused by AQP4-
antibody alone (Supplement table 1). For CDC, “homologous re-
striction” cannot be ignored. Homologous restriction indicates that
the membrane complement regulators in human cells inhibit the
human complement and thereby prevent cell damage, but such a
cell protective mechanism does not operate when the comple-
ments are from other species [21]. Thus, in vivo or in vitro studies
using cells and complements derived from heterogeneous species
may result in an over-estimation of CDC, although there have been
no comprehensive studies of cytotoxicity in AQP4-expressing hu-
man astrocytes by human AQP4-antibody and human
complement.2. Materials and methods
2.1. Puriﬁed IgG
Sera were obtained from 5 patients with AQP4-antibody-posi-
tive NMO, 3 patients with multiple sclerosis (MS), and 3 healthy
controls. MS patients and controls were seronegative for the
AQP4-antibody. IgG was puriﬁed using ProteinA Sepharose Fast
Flow (GE healthcare, Tokyo, Japan), and the concentration was
adjusted to 10 mg/mL.
2.2. Cells
Primary human astrocytes (CC-2565, Lonza Japan, Tokyo, Ja-
pan) were incubated with AGM BulletKit (Lonza Japan, Tokyo, Ja-
pan). All astrocytes were conﬁrmed to be positively stained for
GFAP by immunoﬂuorescence. Prior to each assay, astrocytes were
incubated at 37 °C and 5% CO2 for 4 days. Conﬂuent primary hu-
man astrocytes were incubated with IgG (5% volume) for 30 min.
After the removal of unbound IgG, we further cultured the cells
with human complement (S1764, Sigma-Aldrich Japan, Tokyo, Ja-
pan) (CH50¼42) or rabbit complement (20% volume) with or
without heat inactivation (56 °C, 30 min). In each experiment, we
observed the morphological changes of the cells in each well at 2–24 h of culture. For the positive controls for AQP4 expression, we
used HEK293 cells transfected with M1-AQP4 vector, which have
been previously reported [22].
2.3. Time-lapse microscopic analysis
For the time-lapse analysis, primary astrocytes were seeded
onto 8-well Lab-Tek II chamber slides (Nalge Nunc International,
Rochester, USA). We observed time-lapse morphological changes
of the cells using ﬂuorescence microscopes (BZ-9000, Keyence,
Osaka, Japan, and FV1000-D and FV1000MPE, Olympus, Tokyo,
Japan). A microscopic cell culture system with an incubator (INU-
ONICS-BP, Tokai-hit, Fujinomiya, Shizuoka, Japan) was also em-
ployed. Time-lapse images of living astrocytes were captured at
15- or 30-second intervals. FM 4–64 dyes (10 μM) were used to
label the plasma membrane. Moreover, to stop the endocytosis of
cells, we used 5 μM of phenylarsine oxide (PAO). To visualize the
AQP4 dynamics in astrocytes, we transfected Venus-M1-AQP4
cDNA (provided by Dr. Abe, Keio University). Venus-M1-AQP4 is a
fusion protein of the ﬂuorescent protein, Venus C-terminal and
N-terminal of M1-AQP4. The Kozak sequence in Venus-M1-AQP4
is optimally transcribed from Venus protein, and it is less possible
to express through leaky scanning or re-initiation.
2.4. Immunohistochemical staining
Cells were grown on coverslips with water-shedding coating
(Matsunami, Kishiwada, Japan). Puriﬁed IgG (0.5 mg/mL) from
patients was applied to the culture media, and the cells were in-
cubated for 30 min at room temperature. Next, the cells were ﬁxed
in 4% paraformaldehyde for 30 min, permeabilized with 0.3% Tri-
ton X-100 in PBS for 10 min, blocked with 10% goat serum for
20 min, and then incubated with primary antibodies overnight.
We used rabbit polyclonal anti-AQP4-IgG (Merck Millipore,
Darmstadt, Germany) directed against the intracellular domain
near the C-terminal and mouse monoclonal anti-C5b-9-IgG (Da-
koCytomation, Glostrup, Denmark) as primary antibodies. Goat
anti-human Alexa ﬂuor 488, goat anti-rabbit Alexa ﬂuor 488, goat
anti-rabbit Alexa ﬂuor 568, and goat anti-mouse Alexa ﬂuor 568
(Invitrogen, Carlsbad, USA), were used for secondary antibodies.
2.5. Western blotting for CD55 and CD59
Astrocytes grown on dishes were washed three times with PBS,
and the membrane fraction was isolated using ProteoExtract
(Merck Millipore, Darmstadt, Germany). Total protein was de-
termined using the BCA assay. Each sample (30 μg per well) was
separated using SDS-PAGE and subsequently transferred onto
polyvinylidene diﬂuoride membrane (Merck Millipore, Darmstadt,
Germany). The membranes were incubated with mouse CD55-
antibody (Acris Antibodies, Herford, Germany) or rabbit CD59-
antibody (Proteintech Group, Rosemont, USA) as primary anti-
bodies for 8 h and then with horseradish peroxidase-conjugated
anti-mouse or anti-rabbit secondary antibody (DakoCytomation,
Glostrup, Denmark). The bands were detected using an enhanced
chemiluminescent detection system (ECLPlus; GE healthcare, To-
kyo, Japan) with an image analyzer (LAS-3000; Fuji Photo Film-
Japan, Kanagawa, Japan).
2.6. siRNA transfection
CD55- and CD59-speciﬁc small interfering RNAs (siRNAs) were
purchased from Invitrogen, Carlsbad, USA (Invitrogen stealth
RNAi). The transfection was performed using Lipofectamine 2000
(Invitrogen, Carlsbad, USA) according to the manufacturer’s
instructions.
Fig. 1. Time-lapse analysis of human astrocytes. (A) Normal medium. Normal astrocytes bound to the slide and moved well. B) AQP4-antibody-positive IgG without
complement caused shrinkage of the astrocytic processes, which was observed after 30 min and became more remarkable at 60 min. (C) Normal medium after AQP4-
antibody treatment. The astrocytic process shrinkage was partially reversible by removing the IgG. (D) Dot plot of the cytoplasmic area in the time-lapse analysis. After
60 min, NMO-IgG-treated astrocytes showed a signiﬁcantly smaller cytoplasmic area than did PBS control. The cytoplasmic area of AQP4-antibody (NMO-IgG)-treated
astrocytes recovered in 60 min after medium change. (E) Time-course of the cytoplasmic area. Astrocytes shrink gradually after NMO-IgG addition. The cytoplasmic area was
recovered after the removal of NMO-IgG from media.
S. Nishiyama et al. / Biochemistry and Biophysics Reports 7 (2016) 45–51 472.7. Propidium iodide assay
Cellular cytotoxicity with or without apoptosis was analyzed
using a propidium iodide (PI) kit (TACS Annexin V-FITC, R&D
Systems, Minneapolis, USA). Astrocytes on an 8-well slide were
incubated with puriﬁed IgG (0.5 mg/mL) or normal medium for
30 min. The media were changed to non-heated complement or
heat-inactivated complement. Next, these cells were incubated for
6 h. After incubation, PI staining was performed according to the
manufacturer’s instructions.
2.8. LDH release assay
LDH release into the supernatant was measured using the Cy-
totoxicity Detection Kit Plus (Roche Diagnostics, Tokyo, Japan).
Prior to the assay, human astrocytes in primary culture were in-
cubated in a 6-well plate for four days, and the media were
completely exchanged prior to the assay. The supernatants in each
well were harvested before and after the application of puriﬁed
IgG (0.5 mg/mL). Next, we removed unbound IgG, and each well
was cultured in the presence of non-heated or heat-inactivated
complements for 3 h. After incubation, we harvested the super-
natants of each well. The conditions were performed in duplicate
for this assay.
2.9. Statistical analysis
To compare the PI positivity, LDH release and cellular nucleic
size, one-factor analysis of variance (ANOVA) was performed using
GraphPad Prism 5.04. When a signiﬁcant difference was observed,
a post-hoc test was performed using the Bonferroni test. Statistical
signiﬁcance was assumed when Po0.05. Image J was used to
determine the size of the astrocyte or for densitometry analyses.3. Results
3.1. NMO-IgG and complement bind to the extracellular-domain of
AQP4-transfected HEK293 cells and human astrocytes in primary
culture
AQP4-transfected HEK293 cells were co-labeled with NMO's
puriﬁed serum IgG and mouse AQP4-antibody, indicating that the
NMO's puriﬁed IgG did bind to the extracellular domain of AQP4
on the membrane of HEK293 cells (Supplement Fig. 1A). Human
primary astrocytes were also co-labeled with the NMO AQP4-an-
tibody and mouse AQP4-antibody (Supplement Fig. 1B). After in-
cubation with puriﬁed IgG following non-heated complement, the
cells were co-labeled for AQP4 and C5b-9 (Supplement Fig. 1C),
which suggested complement activation by the patients’ AQP4-
antibody.
3.2. Reversible shrinkage of astrocytes by the patients’ AQP4-antbi-
body alone
Normal human astrocytes retain their adherent ability and
mobility, even if the medium is exchanged to PBS or medium
(Fig. 1(A)). Puriﬁed AQP4-antibody-positive IgG alone caused
shrinkage of the astrocytic processes and a loss of adherent ability
(Fig. 1(B)). The morphology of the cell bodies changed from star-
shaped to spherical without a change in the nucleus. Moreover, the
astrocytic processes connecting neighboring astrocytes also shrank
and appeared similar to threads. The connections became sparse
with passing time. However, these changes were reversible to
some extent by the removal of IgG (Fig. 1(C)). The cytoplasmic area
was signiﬁcantly smaller than that of control astrocytes (Po0.001,
Fig. 1(D)). In addition, the cytoplasmic area recovered shortly after
the patient's AQP4-antibody was removed from media (Fig. 1(E)).
These ﬁndings were recorded (supplement video 1).
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3.3. Clustering and endocytosis of membraneous AQP4 on astrocytes
by AQP4-antibody alone
We used Venus-human AQP4-transfected astrocytes to observe
the real-time changes in AQP4 expression. In the normal condi-
tion, we observed dominant AQP4 expression on the astrocytic cell
membrane (Fig. 2(A), D). In contrast, AQP4-transfected astrocytes
cultured in media containing the NMO's puriﬁed IgG showed Ve-
nus-AQP4 clusters on the membrane after from 30 min (Fig. 2
(B) and supplement video 2). Next, endocytosis of Venus-AQP4
occurred sequentially (Fig. 2(C)). During the cluster formation of
Venus-AQP4, the astrocytic processes gradually shrank and be-
came detached from the dish (Fig. 2(B), C, supplement video 1).
Furthermore, when the medium was changed to fresh medium
that did not contain AQP4-antibody, the normal morphology of the
astrocytes were gradually restored within 4 h. In addition, the
recovery of AQP4 expression on the membrane of astrocytes wasFig. 2. Time-lapse analysis of human AQP4-transfected astrocytes. A) Venus-AQP4-tran
untreated medium. B) Once the NMO's puriﬁed IgG was applied, Venus-AQP4 transfect
foot processes, and balloon-like changes in the cell bodies. C) Next, the AQP4 clusters
transfected human astrocytes in normal medium. Cells in normal condition showed A
normal medium 24 h after a 2-hour AQP4-antibody treatment. Astrocytes appeared nor
membrane. Endosomes of degrading AQP4 are shown in the cytoplasm. F) Venus-AQP4
There were many AQP4 clusters on their membrane but there was no endocytosis.visible after 24 h (Fig. 2(E)), when some internalized AQP4 pro-
teins in the cytoplasm could still be observed.
Supplementary material related to this article can be found
online at http://dx.doi.org/10.1016/j.bbrep.2016.05.012.
Puriﬁed IgG obtained from MS patients and healthy controls
did not cause these astrocytic changes. PAO-treated astrocytes
with Venus-AQP4 vector showed AQP4 clusters on the membrane
but not AQP4 endocytosis (Fig. 2(F)).
3.4. Differential cytotoxic effects between human complement and
rabbit complement
Following the application of non-heated human complements,
the cellular AQP4-immunoreactivity was lost, and the cell bodies
and nuclei started to gradually swell. The LDH release in super-
natants of astrocytes treated with AQP4-antibody and non-heated
complements were signiﬁcantly higher compared to other groups
(Fig. 3(A)). Moreover, astrocytes treated with the patient's
AQP4-antibody and non-heated rabbit complements had a sig-
niﬁcantly larger nuclear area than did those treated with patient'ssfected astrocytes showed green ﬂuorescence in the membrane (Red: FM-dye) in
ed in astrocytes demonstrated clusters on the membrane (arrow), shrinkage of the
entered into the cell body, which indicated endocytosis of AQP4. D) Venus-AQP4-
QP4 localization on the cell membrane. E) Venus-AQP4-transfected astrocytes in
mal in size and foot processes and AQP4 expression was partially recovered on the
-transfected astrocyte in medium with PAO after NMO-IgG treatment for 30 min.
Fig. 3. Human and rabbit complement-dependent cytotoxicity in human astrocytes. A) LDH assay results. In astrocyte-culture supernatants with non-heated complement
after puriﬁed IgG treatment, LDH release was signiﬁcantly higher compared to those by heat-inactivated complement or normal media alone. Moreover, LDH release in the
supernatants with non-heated rabbit complement was signiﬁcantly higher than that with non-heated human complement. C: non-heated complement, HIC: Heat-in-
activated complement,*: Po0.0001. B) Results of cellular nuclear size. After 60-minute treatment with human or rabbit complement, astrocytic nuclear size pre-treated with
NMO’s puriﬁed IgG was signiﬁcantly larger compared with other conditions. In addition, there was a signiﬁcant difference in nuclear size between non-heated rabbit and
human complements. C: non-heated complement, HIC: Heat-inactivated complement,*: Po0.0001. C) Time-course of propidium iodide (PI) positivity. PI assays showed a
signiﬁcant increase in the percentage of positive cells after exposure to AQP4-antibody (NMO-IgG) and non-heated rabbit complement compared with non-heated human
complement.
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Fig. 3(B)). Taken together, these data suggest that “homologous
restriction” occurred in this in vitro model; that is, human astro-
cytic complement inhibitory protein had a limited protective effect
against rabbit complement.
PI positivities were increased in both rabbit and human com-
plement over time (Fig. 3(C)). The percentage of PI-positive cells
after exposure to the patient's AQP4-antibody and non-heated
rabbit complement was signiﬁcantly increased (Po0.01) com-
pared with the value of AQP4-antibody and non-heated human
complement. These data indicated that the cytotoxic effect of
human complement against astrocyte treated with AQP4-antibody
was much slower than previously reported [12].
3.5. Effect of siRNA of human complement inhibitory proteins CD55
and CD59
We suspected that the relative protection of human astrocytes
against the cytotoxic effect of human complement was due to the
complement inhibitory protein on the astrocytic membrane. There
are four known complement inhibitory proteins: CD35, CD46,
CD55, and CD59. In this model, CD55 and CD59 were expressed on
the astrocytic membrane, as been conﬁrmed using immunostain-
ing and western blotting (Fig. 4(A)). The PI assays showed a sig-
niﬁcant increase in the percentage of PI-positive cells after CD55-
siRNA-transfection compared with non-siRNA-transfected astro-
cyte. Transfection of CD59 siRNAs also showed a smaller effect in
PI positivity. PI positivity in CD55- and CD59-siRNA-transfectedastrocytes treated with human complement was not different
from astrocytes treated with rabbit complement (Fig. 4(B)). Fur-
thermore, LDH release in the supernatant of these siRNA-trans-
fected astrocytes showed similar results to the PI positivity data
(P¼0.1105, Supplement Fig. 1E).4. Discussion
In the present study, we found that transmembrane AQP4 be-
came clustered on the cell surface of human astrocytes following
the application of the patient's AQP4-antibody in the absence of
human complements and that it was subsequently endocytosed.
This process was partially reversible after removing AQP4-anti-
body from the culture media, as previously reported for M1-AQP4-
transfected kidney cells (HEK293) by Hinson et al. [12]. However,
we further showed that these AQP4-antibody-mediated changes
in AQP4 most likely resulted in altered motility and adherence of
astrocytes, which may contribute to the pathological process, in-
cluding abnormal neuron-glial interactions in NMO. Selective
AQP4 loss without astrocyte destruction was reported by Misu and
colleagues as Type 4 lesion in six different lesion types in NMO
[10]. Thus, it is interesting to compare the localization of Type
4 lesions and IgG deposition in autopsied NMO cases. Anchoring
proteins, such as syntrophin or dystrophin, are closely related to
AQP4 expression, and the altered expression of AQP4 observed in
the present study might affect both these anchoring proteins as
well as other membrane proteins that function to maintain
Fig. 4. Results of the cytotoxic assay. A) Results of immunostaining and western blotting of complement regulatory protein in the astrocyte. CD55 and CD59 were observed
by immunostaining of cultured human astrocytes and western blotting of the membrane fraction. In addition, CD35 and CD46 on the cultured astrocyte were not detected in
the immunostaining and western blotting. B) Results of propidium iodide (PI) positivity at 60 min after complement treatment. PI assays showed a signiﬁcant increase in the
percentage of PI-positive cells after CD55-siRNAs transfection compared with non-siRNA treated astrocyte. Transfection of CD59-siRNAs showed a limited effect on PI
positivity. PI positivity after the transfection of CD55 and CD59 with human complement showed no signiﬁcant difference against astrocytes with rabbit complement.
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cytes treated with AQP4-antibody could result from altered water
permeability in the astrocytic membrane; however, competing
reports on whether AQP4-antibody affects the passage of water
molecules through AQP4 water channel have emerged [18,23,24].
Complement-dependent AQP4-antibody-mediated astrocytic
lysis has been previously reported, and such lesions correspond to
Type 1 lesion in Misu's classiﬁcation of NMO lesion. However,
because a majority of previous studies used target cells and
complements that were from different species, as shown in Sup-
plement table 1, the effect of “homologous restriction” by com-
plement inhibitory proteins was not evaluated. In our study, we
found that the patient's AQP4-antibody-mediated cytotoxicity to
human AQP4-tranfected astrocytes by human complements was a
much slower process than that by rabbit complements. In ex-
periments with CD55-/CD59-siRNA-transfected astrocytes, CD55
was more closely related to “homologous restriction” than CD59
was. Recently, Saadoun and Papadopulos reported that these
complement inhibitory proteins were expressed in other organs
but not in the brain, which may explain why NMO primarily da-
mages the central nervous system but spares peripheral organs
[25]. It is intriguing to attribute the selective central nervous
system involvement in NMO to no “homologous restriction”, but
another study reported the expression of CD55 and CD59 in the
brain [26]. Matiello et al. showed that AQP4-mRNA and proteins
(both M1- and M23-AQP4) were much more highly expressed in
the optic nerves and spinal cord than in other brain regions, which
may contribute to the predilection of the optic nerve and spinal
cord to NMO pathology [4]. Thus, we should analyze the locali-
zation of complement inhibitory proteins in the optic nerves,
spinal cord and other regions of the central nervous system to
determine whether “homologous restriction” is unevenly
distributed.
There are some limitations in this study: 1. because we used
short-term primary human astrocyte cultures, longitudinal chan-
ges in astrocytes treated with the patient's AQP4-antibody and
complements need to be evaluated in in vivo models. 2. Only M1-
AQP4-transfected astrocytes were used in the present study. M23-
AQP4 forms an orthogonal array of particles, and AQP4-antibodytends to bind more tightly to M23-AQP4 [25]. Thus, the morpho-
logical and functional changes and cytolysis observed in M23-
AQP4-transfected astrocytes may not be identical to those ob-
served in M1-AQP4-transfecrted astrocytes in the present study.Disclosure
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